Tyrosine kinases in rheumatoid arthritis

Journal of Inflammation

Volumn 8, Issue , 2011, Pages

  Okamoto, Hiroshi ^a   Kobayashi, Akiko ^a  

^a Minami Otsuka Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARRY 162; FASUDIL; FENOFIBRATE; FOSTAMATINIB; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; JANUS KINASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PAMAPIMOD; PLACEBO; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; TASOCITINIB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VX 702;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HYPERTENSION; INFECTION; NEPHRITIS; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 80052034813     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-8-21     Document Type: Review

References (60)

1. Rheumatoid arthritis. Feldmann M, Brennan FM, Maini RN, Cell 1996 85 307 10 10.1016/S0092-8674(00)81109-5 8616886 (Pubitemid 26160702)
2. Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon. Hopkins SJ, Meager A, Clin Exp Immunol 1988 73 88 92 2458872
3. -2008 Molecular targets of rheumatoid arthritis. Okamoto H, Hoshi D, Kiire A, Yamanaka H, Kamatani N, Inflamm Allergy Drug Targets 2008 7 53 66 10.2174/187152808784165199 18473901 (Pubitemid 351663646)
4. Review: angiogenesis: implications for rheumatoid arthritis. Koch AE, Arthritis Rheum 1998 41 951 62 10.1002/1529-0131(199806)41:6<951::AID- ART2>3.0.CO;2-D 9627005 (Pubitemid 28265398)
5. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM, Ferrara N, J Immunol 1994 152 4149 56 7511670 (Pubitemid 24111088)
6. Are Th17 cells an appropriate new target in the treatment of rheumatoid arthritis? Kato H, Fox DA, Clin Transl Sci 2010 3 319 26 10.1111/j.1752-8062. 2010.00233.x 21167010
7. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I, Blood 2008 112 2340 52 10.1182/blood-2008-01-133967 18617638
8. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Wei G, Wei L, Zhu J, Zang C, Hu-Li J, Yao Z, Cui K, Kanno Y, Roh TY, Watford WT, Schones DE, Peng W, Sun HW, Paul WE, O'Shea JJ, Zhao K, Immunity 2009 30 155 67 10.1016/j.immuni.2008.12.009 19144320
9. Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. Sano H, Engleka K, Mathern P, Hla T, Crofford LJ, Remmers EF, Jelsema CL, Goldmuntz E, Maciag T, Wilder RL, J Clin Invest 1993 91 553 65 10.1172/JCI116235 7679410 (Pubitemid 23064141)
10. Role of mitogen-activatedprotein kinase kinase kinases in signal integration. Cuevas BD, Abell AN, Johnson GL, Oncogene 2007 26 3159 3171 10.1038/sj.onc.1210409 17496913 (Pubitemid 46763012)
11. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Damjanov N, Kauffman RS, Spencer-Green GT, Arthritis Rheum 2009 60 1232 1241 10.1002/art.24485 19404957
12. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP, Arthritis Rheum 2009 60 335 344 10.1002/art.24266 19180516
13. Intracellular signal pathways: potential for therapies. Mavers M, Ruderman EM, Perlman H, Curr Rheumatol Rep 2009 11 378 85 10.1007/s11926-009- 0054-9 19772834
14. Selectivity and therapeutic inhibition of kinases: to be or not to be? Ghoreschi K, Laurence A, O'Shea JJ, Nat Immunol 2009 10 356 60 10.1038/ni.1701 19295632
15. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, et al. Nature 1995 377 65 8 10.1038/377065a0 7659163
16. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ, Leonard WJ, Science 1995 270 797 800 10.1126/science.270.5237.797 7481768
17. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Kawamura M, McVicar DW, Johnston JA, Blake TB, Chen YQ, Lal BK, Lloyd AR, Kelvin DJ, Staples JE, Ortaldo JR, O'Shea JJ, Proc Natl Acad Sci USA 1994 91 6374 8 10.1073/pnas.91.14.6374 8022790 (Pubitemid 24200663)
18. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, Takada H, Hara T, Kawamura N, Ariga T, Kaneko H, Kondo N, Tsuge I, Yachie A, Sakiyama Y, Iwata T, Bessho F, Ohishi T, Joh K, Imai K, Kogawa K, Shinohara M, Fujieda M, Wakiguchi H, Pasic S, Abinun M, Ochs HD, Renner ED, Jansson A, Belohradsky BH, Metin A, Shimizu N, Mizutani S, Miyawaki T, Nonoyama S, Karasuyama H, Immunity 2006 25 745 55 10.1016/j.immuni.2006.09.009 17088085 (Pubitemid 46131400)
19. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ, Proc Natl Acad Sci USA 2006 103 8137 42 10.1073/pnas.0600666103 16698929 (Pubitemid 43801065)
20. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A, J Clin Invest 2001 108 1781 8 11748261 (Pubitemid 34015123)
21. The Jak-STAT pathway in rheumatoid arthritis. Walker JG, Smith MD, J Rheumatol 2005 32 1650 1653 16142855 (Pubitemid 41324798)
22. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino) piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ, J Med Chem 2008 51 8012 8018 10.1021/jm801142b 19053756
23. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH, Arthritis Rheum 2009 60 1895 905 10.1002/art.24567 19565475
24. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH, Ann Rheum Dis 2010 69 413 6 10.1136/ard.2009.108159 19587388
25. The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation. Rao N, Ghosh AK, Ota S, Zhou P, Reddi AL, Hakezi K, Druker BK, Wu J, Band H, EMBO J 2001 20 7085 95 10.1093/emboj/20.24.7085 11742985 (Pubitemid 34062300)
26. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E, Clin Immunol 2007 124 244 57 10.1016/j.clim.2007.03.543 17537677 (Pubitemid 47247604)
27. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E, Arthritis Rheum 2008 58 3309 18 10.1002/art.23992 18975322
28. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, Dicarlo J, White ML, O-Brien M, Grossbard EB, Magilavy DB, Arthritis Rheum 2010
29. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB, N Engl J Med 2010 363 1303 12 10.1056/NEJMoa1000500 20879879
30. possible involvement of protein tyrosine kinase and phospholipase C-gamma. Anzai N, Gotoh A, Shibayama H, Broxmeyer HE, Modulation of integrin function in hematopoietic progenitor cells by CD43 engagement, Blood 1999 93 3317 26 10233884
31. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, Firestein GS, J Pharmacol Exp Ther 2006 317 571 578 10.1124/jpet.105.097436 16452391
32. Lck activity controls CD4/CD8 T cell lineage commitment. Hernández-Hoyos G, Sohn SJ, Rothenberg EV, Alberola-Ila J, Immunity 2000 12 313 22 10.1016/S1074-7613(00)80184-3 10755618
33. Autoimmune disease in Lyn-deficient mice is dependent on an inflammatory environment established by IL-6. Tsantikos E, Oracki SA, Quilici C, Anderson GP, Tarlinton DM, Hibbs ML, J Immunol 2010 184 1348 60 10.4049/jimmunol.0901878 20042579
34. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC, Arthritis Rheum 2010 62 2086 92 20222110
35. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. Okamoto H, Kobayashi A, N Engl J Med 2011 364 83 4 21208114
36. Molecular aspects of rheumatoid arthritis: role of transcription factors. Okamoto H, Cujec TP, Yamanaka H, Kamatani N, FEBS J 2008 275 4463 70 10.1111/j.1742-4658.2008.06582.x 18662303
37. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA, EMBO J 1995 14 2876 2883 7796813
38. Regulation of NF-kappa B and disease control: identification of a novel serine kinase and thioredoxin as effectors for signal transduction pathway for NF-kappa B activation. Okamoto T, Sakurada S, Yang JP, Merin JP, Curr Top Cell Regul 1997 35 149 161 9192179
39. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M, Nature 1997 388 548 554 10.1038/41493 9252186 (Pubitemid 27339997)
40. IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A, Science 1997 278 860 866 10.1126/science.278.5339.860 9346484 (Pubitemid 27467923)
41. The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M, Cell 1997 91 243 252 10.1016/S0092-8674(00)80406-7 9346241 (Pubitemid 27456391)
42. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Rothwarf DM, Zandi E, Natoli G, Karin M, Nature 1998 395 297 300 10.1038/26261 9751060 (Pubitemid 28447557)
43. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K, Proc Natl Acad Sci USA 1998 95 3537 3542 10.1073/pnas.95.7.3537 9520401 (Pubitemid 28173163)
44. NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Ling L, Cao Z, Goeddel DV, Proc Natl Acad Sci USA 1998 95 3792 797 10.1073/pnas.95.7.3792 9520446 (Pubitemid 28173208)
45. MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Lee FS, Peters RT, Dang LC, Maniatis T, Proc Natl Acad Sci USA 1998 95 9319 9324 10.1073/pnas.95.16.9319 9689078 (Pubitemid 28506229)
46. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV, J Clin Invest 2005 115 1848 1854 10.1172/JCI23763 15937549 (Pubitemid 40979723)
47. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP, Arthritis Res Ther 2006 8 86 10.1186/ar1958 16684367
48. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N, Clin Exp Rheumatol 2005 23 323 330 15971419 (Pubitemid 40823539)
49. Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase. Asano T, Suzuki T, Tsuchiya M, Satoh S, Ikegaki I, Shibuya M, Suzuki Y, Hidaka H, Br J Pharmacol 1989 98 1091 1100 2611484 (Pubitemid 20011061)
50. Mechanism of action of a novel antivasospasm drug, HA1077. Asano T, Ikegaki I, Satoh S, Suzuki Y, Shibuya M, Takayasu M, Hidaka H, J Pharmacol Exp Ther 1987 241 1033 1040 3598899
51. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, J Neurosurg 1992 76 571 577 10.3171/jns.1992.76.4.0571 1545249
52. Inhibition of human immunodeficiency virus type 1 replication by a bioavailable serine/threonine kinase inhibitor, fasudil hydrochloride. Sato T, Asamitsu K, Yang JP, Takahashi N, Tetsuka T, Yoneyama A, Kanagawa A, Okamoto T, AIDS Res Hum Retroviruses 1998 14 293 298 10.1089/aid.1998.14.293 9519889 (Pubitemid 28110666)
53. Inhibition of NF-kappaB signaling by fasudil as a potential therapeutic strategy for rheumatoid arthritis. Okamoto H, Yoshio T, Kaneko H, Yamanaka H, Arthritis Rheum 2010 62 82 92 10.1002/art.25063 20039418
54. The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Cujec TP, Okamoto H, Fujinaga K, Meyer J, Chamberlin H, Morgan DO, Peterlin BM, Genes Dev 1997 11 2645 57 10.1101/gad.11.20.2645 9334327 (Pubitemid 27452388)
55. HIV-1 replication is inhibited by a pseudo-substrate peptide that blocks Tat transactivation. Okamoto H, Cujec TP, Peterlin BM, Okamoto T, Virology 2000 270 337 44 10.1006/viro.2000.0311 10792993 (Pubitemid 30333681)
56. Manipulating immune responses with immunosuppressive agents that target NFAT. Kiani A, Rao A, Aramburu J, Immunity 2000 12 359 72 10.1016/S1074-7613(00) 80188-0 10795734
57. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Morishita R, Tomita N, Kaneda Y, Ogihara T, Curr Opin Pharmacol 2004 4 139 46 10.1016/j.coph.2003.10.008 15063357 (Pubitemid 38444048)
58. Identification of JAK/STAT signalling components by genome-wide RNA interference. Müller P, Kuttenkeuler D, Gesellchen V, Zeidler MP, Boutros M, Nature 2005 436 871 5 10.1038/nature03869 16094372 (Pubitemid 41160648)
59. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Vanags D, Williams B, Johnson B, Hall S, Nash P, Taylor A, Weiss J, Feeney D, Lancet 2006 368 855 63 10.1016/S0140-6736(06)69210-6 16950363 (Pubitemid 44292809)
60. Chaperonin 10 for rheumatoid arthritis. Okamoto H, Lancet 2006 368 1961 17141697 (Pubitemid 44821372)